Gastrodyne is developing a swallowable, biodegradable smart capsule that autonomously navigates the GI tract and delivers therapy exactly at the site of disease — no needles, no infusion visits.
Current therapies force a brutal trade-off: systemic drugs cause widespread side effects, while targeted procedures are invasive, expensive, and poorly tolerated.
Oral biologics and steroids flood the entire body to treat a localized lesion. Patients endure immunosuppression, infections, and long-term organ damage for treatment that may not even reach the target site.
Endoscopic injections require sedation, specialist scheduling, and recovery time. For Crohn's patients needing ongoing therapy, repeated invasive procedures destroy compliance and quality of life.
Diagnostic capsules like PillCam image but can't treat. Enemas can't reach Crohn's small-bowel disease. A persistent gap exists for 2M+ North American IBD patients — completely unaddressed.
Gastrodyne's platform combines dual-trigger localization, on-board imaging, and biodegradable drug delivery in a single swallowable device the size of a vitamin.
pH sensing combined with microbiome enzyme layers provides fail-safe regional accuracy — no external hardware, no operator input required.
AMS NanEye camera with FPGA pipeline and CNN-based tissue classification. Working prototype validated at 75% diagnostic accuracy on the CROHN-IPI dataset.
Microneedle-based actuation delivers payload directly into GI tissue. Initial targets: budesonide and mesalamine for localized IBD inflammation.
Timed self-dissolution eliminates capsule retention risk — a critical physician concern addressed by design, not regulatory workaround.
Leads end-to-end product development, system integration, and regulatory strategy. Drives cross-functional collaboration from prototype to clinical translation.
Develops and trains AI models for sensor data interpretation and autonomous localization. Designed the FPGA imaging pipeline currently validated in hardware.
Guides drug formulation strategy, delivery design, and preclinical documentation. Provides scientific oversight across regulatory and clinical submissions.
Provides clinical and procedural insight to guide device validation. Supports clinical translation strategy and early feasibility study design.
We're actively seeking early feasibility study partners, grant collaborators, and seed-stage investors who share our vision for precision GI medicine.